Business Context and Reporting Period
Company: Arrowhead Pharmaceuticals, Inc. (ARWR)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended September 30, 2025
Business Overview: Arrowhead develops RNA interference (RNAi) therapeutics to treat intractable diseases by silencing disease-causing genes. The company utilizes its proprietary TRiM platform for tissue-specific delivery. In November 2025, the company achieved a transformational milestone with the FDA approval of REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome (FCS), marking its first commercial launch.
Key Financial Metrics
| Metric (in millions) | Fiscal 2025 | Fiscal 2024 | Change |
|---|---|---|---|
| Revenue | $829.4 | $3.6 | +$825.9 (23,257%) |
| Operating Income (Loss) | $98.3 | $(601.1) | Improvement of $699.4 |
| Net Loss Attributable to Arrowhead | $(1.6) | $(599.5) | Improvement of $597.9 |
| Net Loss Per Share (Diluted) | $(0.01) | $(5.00) | Significant reduction |
| Cash, Cash Equivalents, and Restricted Cash | $226.5 | $102.7 | +$123.8 |
| Available-for-Sale Securities | $692.8 | $578.3 | +$114.5 |
| Total Liquidity (Cash + Investments) | $919.3 | $681.0 | +$238.3 |
| Debt (Credit Facility) | $254.9 (Net) | $393.2 (Net) | Reduction of $138.3 |
Note: Debt figures represent the Credit Facility balance net of current portion and unamortized costs. The facility has a 15% interest rate paid in-kind.
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased from $3.6 million in 2024 to $829.4 million in 2025. This was driven primarily by:
- Sarepta Collaboration: $696.8 million recognized, including a $500 million upfront payment and a $100 million milestone (partially settled in stock).
- Sanofi/Visirna Transaction: $130.0 million recognized from the sale of Greater China rights for plozasiran.
- GSK Milestone: $2.6 million recognized.
- Profitability Shift: The company moved from an operating loss of $601.1 million to an operating income of $98.3 million, largely due to the massive revenue recognition from licensing deals offsetting increased R&D and G&A expenses.
- Expense Growth:
- R&D Expenses: Increased 20% to $607.2 million, driven by higher candidate costs ($347.6 million) as the pipeline advanced into Phase 3 trials.
- G&A Expenses: Increased 25% to $123.9 million, primarily due to professional services related to commercialization preparation and business development.
- Debt Reduction: The company repaid $201.6 million of its $500 million Credit Facility during the year, reducing the outstanding balance significantly.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Commercialization: REDEMPLO was approved by the FDA on November 18, 2025. The company has built a commercial organization for FCS and plans to expand for Severe Hypertriglyceridemia (sHTG) pending Phase 3 results (SHASTA-3, SHASTA-4, SHASTA-5).
- Pipeline Progress:
- Zodasiran (HoFH): Initiated Phase 3 YOSEMITE trial.
- ARO-DIMER-PA (Mixed Hyperlipidemia): Filed for Phase 1/2a clearance; first dual-gene silencing candidate.
- ARO-MAPT (Alzheimer's): Filed for Phase 1/2a clearance; utilizes new CNS delivery system.
- Liquidity: Management expects sufficient liquidity to fund operations for at least the next 12 months based on current cash, investments, and operating plans.
Risks and Contingencies
- Patent Litigation: Ionis Pharmaceuticals filed a patent infringement lawsuit (Sept 2025) regarding U.S. Patent No. 9,593,333, alleging infringement by plozasiran. Arrowhead filed a declaratory judgment action to invalidate the patent. Outcome is uncertain and could impact commercialization.
- Debt Covenants: The Sixth Street Credit Facility includes liquidity covenants tied to market capitalization and restrictions on asset sales/licensing of core IP. Failure to comply could accelerate repayment.
- Regulatory Uncertainty: While REDEMPLO is approved for FCS, approval for the broader sHTG indication is not guaranteed. Regulatory standards may evolve, potentially delaying approvals.
- Manufacturing Reliance: The company relies on third-party manufacturers for REDEMPLO drug substance and product, creating supply chain risks.
Key Facts for Investor Verification
- REDEMPLO Approval Status: Verify the specific terms of the FDA approval for FCS and the timeline for the supplemental NDA for sHTG.
- Ionis Litigation: Monitor the status of the patent infringement lawsuit filed by Ionis Pharmaceuticals, as a negative outcome could block REDEMPLO sales.
- Sarepta Milestone Payments: Confirm the timing and conditions for the remaining $250 million in near-term milestone payments from Sarepta.
- Debt Service: Review the specific prepayment requirements and interest accretion on the Sixth Street Credit Facility, particularly the "Multiple of Invested Capital" (MOIC) payment obligations.
- Commercial Execution: Assess the company's ability to scale commercial operations for REDEMPLO given its limited prior experience in product sales.